MicroRNA expression profiling of mature ovarian teratomas

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 35-38

  Ding, Ye ^a   Gu, Xiao Yan ^a   Xu, Feng ^a   Shi, Xiao Yan ^a   Yang, Da Zheng ^a   Zhong, Jian ^a   Wang, Su Min ^a  

^a WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Mature ovarian teratomas; Microarrays; MicroRNAs

Indexed keywords

MICRORNA; MICRORNA 142 3P; MICRORNA 19A; MICRORNA 214; MICRORNA 22; MICRORNA 26B; MICRORNA 34A; MICRORNA 421; MICRORNA 492; MICRORNA 520A 5P; MICRORNA 555; MICRORNA 620; MICRORNA 629; MICRORNA 657; MICRORNA 720; MICRORNA 934; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY TERATOMA; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84855266327     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.438     Document Type: Article

References (25)

1. Matz MH: Benign cystic teratomas of the ovary: a review. Obstet Gynecol Surv 16: 591-594, 1961.
2. Lakkis WG, Martin MC and Gelfand MM: Benign cystic teratoma of the ovary: a 6-year review. Can J Surg 28: 444-446, 1985.
3. Ayhan A, Bukulmez O, Genc C, Karamursel BS and Ayhan A: Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol 88: 153-157, 2000.
4. Emin U, Tayfun G, Cantekin I, Ozlem UB, Umit B and Leyla M: Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet 279: 145-147, 2009.
5. Park SB, Kim JK, Kim KR and Cho KS: Imaging findings of complications and unusual manifestations of ovarian teratomas. Radiographics 28: 969-983, 2008.
6. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
7. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
8. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Shah AA, Meese E and Blin N: Profiling of regulatory microRNA transcriptomes in various biological processes: a review. J Appl Genet 51: 501-507, 2010.
10. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H and Nikitin AY: Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128, 2010.
11. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA and Mukherjee P: MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 69: 9090-9095, 2009.
12. Miura K, Obama M, Yun K, Masuzaki H, Ikeda Y, Yoshimura S, Akashi T, Niikawa N, Ishimaru T and Jinno Y: Methylation imprinting of H19 and SNRPN genes in human benign ovarian teratomas. Am J Hum Genet 65: 1359-1367, 1999.
13. Lakshmipathy U, Love B, Goff LA, Jornsten R, Graichen R, Hart RP and Chesnut JD: MicroRNA expression pattern of undifferentiated and differentiated human embryonic stem cells. Stem Cells 16: 1003-1016, 2007.
14. von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A and Schmid I: MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 53: 833-842, 2011.
15. Hu H, Du L, Nagabayashi G, Seeger RC and Gatti RA: ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 107: 1506-1511, 2010.
16. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S and Han J: Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest 118: 1944-1954, 2008.
17. Vaksman O, Stavnes HT, Kærn J, Trope CG, Davidson B and Reich R: miRNA profiling along tumor progression in ovarian carcinoma. J Cell Mol Med 15: 1593-602, 2010.
18. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B and O'Leary J: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35, 2008.
19. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000.
20. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967, 2005.
21. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP and Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166, 2007.
22. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004-7009, 2008.
23. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A and Ponte JF: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983: 84-100, 2003.
24. Lee H, Rezai-Zadeh N and Seto E: Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 24: 765-773, 2004.
25. Simboeck E and Di Croce L: HDAC1, a novel marker for benign teratomas. EMBO J 29: 3992-4007, 2010.